Latest filing published 03 Dec 2025 for Sonnet BioTherapeutics Holdings, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Susan Dexter: trading record in brief
Susan Dexter is a declared insider of Sonnet BioTherapeutics Holdings, Inc. (senior executive), with filings sourced from SEC (Form 4). We count 10 filings; the first trade dates from 2 July 2020 and the latest from 2 December 2025.
The open-market record is one-sided, with 1 purchase worth €6,456 and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 7 share grants.
The record was last updated on 3 December 2025 with a transaction in Sonnet BioTherapeutics Holdings, Inc. The clock since the last published purchase (15 June 2023) now reads 1,243 days. Typically, a trade is published a median of 6 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Susan Dexter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 9,643 sharesCommon StockSEC:0001493152-25-026068:0
- 8,000 sharesCommon StockSEC:0001641172-25-019779:0
- 1,452 sharesCommon StockSEC:0001493152-24-048958:0
- 10,000 shares@ US$0.7020.5% of flowCommon StockSEC:0001493152-23-021430:0Canonical exit: 12 Sept 2023 (T+90)
- 14,627 sharesCommon StockSEC:0001493152-23-005468:0
- 14,627 sharesCommon StockSEC:0001493152-22-036321:0
- 63,104 sharesCommon StockSEC:0001493152-22-009481:0
- 10,145 shares@ US$1.5166.0% of flowCommon StockSEC:0001493152-21-013203:0
8 of 8 declarations